mental-wellness

Trend: Harnessing digital tech to improve mental health and wellness

by

From mind­ful­ness apps to vir­tu­al ther­a­py ses­sions, dig­i­tal tools offer instant access to well­ness resources (The Globe and Mail):

In 2015, Brie Code was work­ing at lead­ing video game com­pa­ny Ubisoft as lead arti­fi­cial intel­li­gence pro­gram­mer when she real­ized that many peo­ple she knew – about half, by her esti­ma­tion – found video games bor­ing. [Read more…] about Trend: Har­ness­ing dig­i­tal tech to improve men­tal health and wellness

Happify Health raises $73M to deepen partnerships with pharmaceutical companies and insurance payers

by

Hap­pi­fy Health rais­es $73M to expand its dig­i­tal ther­a­peu­tic care deliv­ery capa­bil­i­ties (Mobi­Health News):

Found­ed in 2012, Hap­pi­fy is best known for dig­i­tal pro­grams that pro­vid­ed auto­mat­ed self-guid­ed sup­port across var­i­ous areas of men­tal health and well­ness, such as stress man­age­ment for employ­ees or health plan mem­bers. Should the user need addi­tion­al sup­port, the plat­form can also facil­i­tate a refer­ral to third-par­ty coach­ing, ther­a­py, telemed­i­cine or oth­er avail­able resources. [Read more…] about Hap­pi­fy Health rais­es $73M to deep­en part­ner­ships with phar­ma­ceu­ti­cal com­pa­nies and insur­ance payers

Calm raises $75 million, expands into corporate mental health and wellness

by

Calm Med­i­ta­tion App Hits $2 Bil­lion Val­ue With Light­speed, Gold­man Back­ing (Bloomberg News):

Calm, mak­er of a med­i­ta­tion, sleep and relax­ation app, dou­bled its val­u­a­tion to $2 bil­lion after rais­ing cap­i­tal from exist­ing back­ers includ­ing Light­speed Ven­ture Part­ners, TPG and Insight Part­ners. [Read more…] about Calm rais­es $75 mil­lion, expands into cor­po­rate men­tal health and wellness

What will the ‘Peloton for mental health’ look like five years from now? And, who will develop it?

by

Mind­Labs rais­es £1.4M for its new plat­form, a ‘Pelo­ton for men­tal health’ (TechCrunch):

Ide­al­ly, men­tal well­ness should be con­sid­ered part of a healthy dai­ly rou­tine, like exer­cise. But even exer­cise is dif­fi­cult to turn into a reg­u­lar habit. Pelo­ton addressed phys­i­cal fit­ness by com­bin­ing smart sta­tion­ary bikes with live class­es and com­mu­ni­ty fea­tures to cre­ate an engag­ing expe­ri­ence. Now a new start­up, Mind­Labs, is tak­ing a sim­i­lar approach to men­tal well­ness [Read more…] about What will the ‘Pelo­ton for men­tal health’ look like five years from now? And, who will devel­op it?

Meditation apps have gone mainstream in the covid-19 era

by

__

1. Best med­i­ta­tion apps: prac­tice mind­ful­ness with Head­space, Calm and more (TechRadar):

“The best med­i­ta­tion apps could help you to sleep bet­ter, reduce your stress lev­els and find some much-need­ed inner peace. But giv­en the sit­u­a­tion right now with Covid-19, even if med­i­ta­tion apps just give you a break from the news and a chance to chill out for ten min­utes, they’re more than worth it.

Head­space, one of the most pop­u­lar med­i­ta­tion apps around, first launched 10 years ago. Since then, hun­dreds of oth­er med­i­ta­tion apps have been cre­at­ed and that means find­ing the best med­i­ta­tion app for you can be overwhelming.

But when it comes to med­i­ta­tion, choice is a good thing. [Read more…] about Med­i­ta­tion apps have gone main­stream in the covid-19 era

Meditation app Headspace raises $93 million in equity and debt to accelerate clinical validation and geographic expansion

by

Head­space rais­es $93 mil­lion in equi­ty and debt as it pur­sues clin­i­cal val­i­da­tion for mind­ful­ness (TechCrunch):

“Head­space, the Los Ange­les-based mind­ful­ness and med­i­ta­tion com­pa­ny locked in a bit­ter com­pet­i­tive strug­gle with Calm for lead­er­ship in the men­tal well­ness world, has raised new cap­i­tal to try to take the pole position.

The com­pa­ny has just closed on $93 mil­lion in new equi­ty and debt financ­ing [Read more…] about Med­i­ta­tion app Head­space rais­es $93 mil­lion in equi­ty and debt to accel­er­ate clin­i­cal val­i­da­tion and geo­graph­ic expansion